FDA Approves NYVEPRIA — Pfizer Laboratories Div Pfizer Inc

# FDA Approves Pfizer's NYVEPRIA, Expanding Pegfilgrastim Biosimilar Competition The FDA has approved Pfizer's NYVEPRIA (pegfilgrastim-apgf), a biosimilar to the widely-used neutropenia treatment pegfilgrastim, potentially capturing significant market share in a competitive segment expected to see multiple biosimilar entries. The subcutaneous formulation approval positions Pfizer to challenge existing pegfilgrastim competitors and could intensify pricing pressure in the oncology support care market.